Efficacy of eplerenone added to candesartan on left ventricular hypertrophy and fibrosis in hypertensive patients

Efficacy of eplerenone added to candesartan on left ventricular hypertrophy and fibrosis in hypertensive patients - Efficacy of eplerenone added to candesartan in hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003657

Enrollment

Registered

2010-05-24

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

eplerenone 50mg+candesartan 8mg trichlormethiazide 1mg+candesartan 8mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BP 130/85mmHg over in clinic

Exclusion criteria

Exclusion criteria: over 80 years old AMI,PCI, stroke, hospitalization of heart failure within 6 months valvular disease serum creatinin over 1.5mg/dl in male and over 1.3 in female proteinuria liver cirrosis collagen disease cancer chronic inflammatory disease steroid therapy diuretics therapy

Design outcomes

Primary

Measure	Time frame
left ventricular fibrosis left ventricular diastolic dysfunction left ventricular hypertrophy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026